Literature DB >> 11534265

Management of thrombosis in antiphospholipid antibody syndrome.

M Petri1.   

Abstract

Antiphospholipid antibody positive patients are at risk for venous and arterial thrombosis. The risk of recurrent thromboembolism is high. Although the standard of care is high-intensity warfarin after a thromboembolic event, some studies indicate that this degree of anticoagulation is not needed. There is an urgent need of clinical trials to address management of thrombosis in antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11534265     DOI: 10.1016/s0889-857x(05)70225-8

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  5 in total

1.  Long-term treatment of antiphospholipid syndrome-associated cerebral arterial thromboses with intravenous immunoglobulin: a case report.

Authors:  B Arabshahi; E D Thompson; E M Smergel; D P Goldsmith
Journal:  Clin Rheumatol       Date:  2005-12-03       Impact factor: 2.980

2.  Antiphospholipid Antibody Syndrome.

Authors:  Elena Cucurull; Azzudin E. Gharavi; Yamini Menon; Wendell A. Wilson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-04

3.  Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson
Journal:  Stroke       Date:  2014-10-28       Impact factor: 7.914

Review 4.  Antiphospholipid syndrome: an overview.

Authors:  John G Hanly
Journal:  CMAJ       Date:  2003-06-24       Impact factor: 8.262

Review 5.  Antiphospholipid antibodies in pediatrics.

Authors:  Ana I Quintero-Del-Rio
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.